logo-loader
viewScancell Holdings PLC

Scancell receives “significant scientific endorsement” for technology

The company teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge

immunotherapy graphic
The drug developer is at the cutting edge of immunotherapy where the body’s own defences are used to fight disease

Scancell Holdings Plc (LON:SCLP) said it had received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

READ: Scancell makes two experience hires as it gears up for the next development phase

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

While ultimately unsuccessful in landing the top prize, the AIM-listed company was “delighted” its submission made it to the final stages.

"We would like to congratulate the winners of Cancer Research UK's Grand Challenge, and to thank Cancer Research UK for putting the challenge forward to some of the best researchers in the world,” said Professor Lindy Durrant, Scancell’s chief scientific officer.

“The shortlisting of our proposal represents a significant scientific endorsement of Scancell's technology and the team remains committed to meeting the challenges of improving cancer vaccines for all patients.”

The drug developer, which is at the cutting edge of immunotherapy where the body’s own defences are used to fight disease, is currently gearing up to take its lead compound, SCIB1, into phase II clinical trials.

Quick facts: Scancell Holdings PLC

Price: 4.9 GBX

LSE:SCLP
Market: LSE
Market Cap: £22.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read